Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Down 5.8% – What’s Next?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) were down 5.8% on Thursday . The company traded as low as $21.00 and last traded at $21.03. Approximately 218,859 shares traded hands during trading, a decline of 18% from the average daily volume of 265,954 shares. The stock had previously closed at $22.33.

Wall Street Analysts Forecast Growth

Several analysts recently commented on DMRA shares. UBS Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 price target for the company. Wedbush started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, May 28th. They set an “outperform” rating and a $35.00 price objective on the stock. Evercore initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price for the company. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Damora Therapeutics, Inc. Common Stock Stock Down 5.2%

The stock’s 50-day moving average price is $25.06 and its 200 day moving average price is $25.36. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -3.79 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ikarian Capital LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $6,574,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $2,772,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,204,000. Finally, Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $100,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.